drugset / Trial / NCT00674063

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

NCT00674063

Phase 3 Completed 78 enrolled Astellas Pharma Inc Biogen · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis

Timeline

Start
2003-07
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 0.075 mg/kg
Subject Alefacept Protein / enzyme biologic 7.5 mg

Indications